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The Critical Path for Parkinson’s (CPP) Imaging Biomarker and Modeling and Simulation working groups aimed to achieve 
qualification opinion by the European Medicines Agency (EMA) Committee for Medical Products for Human Use (CHMP) for 
the use of baseline dopamine transporter neuroimaging for patient selection in early Parkinson’s disease clinical trials. This 
paper describes the regulatory science strategy to achieve this goal. CPP is an international consortium of three Parkinson’s 
charities and nine pharmaceutical partners, coordinated by the Critical Path Institute.
There is an urgent need for novel treatments against Parkinson’s 
disease (PD), especially intended to target the earlier stages 
of disease progression. Clinical trials to evaluate these drug 
candidates require tools that allow an optimal selection of trial 
participants, for instance, enrollment of homogeneous popu-
lations in terms of their expected disease progression.1
The US Food and Drug Administration has approved mo-
lecular dopamine transport (DAT) neuroimaging as an ad-
junct diagnostic evaluation to help differentiate essential 
tremor from tremor due to parkinsonian syndromes, whereas 
the European Medicines Agency (EMA) approved DAT im-
aging to detect loss of functional dopaminergic neuron 
terminals in the striatum.2,3 The role of DAT imaging as a drug- 
development tool (DDT) to optimize predictions of motor 
progression was recognized as having potential as an en-
richment biomarker for clinical trials. The EMA Qualification 
of Novel Methodologies in Drug Development pathway is a 
specific regulatory mechanism that facilitates qualification of 
DDTs, such as this application of DAT imaging.4
This paper describes the strategy to achieve qualifi-
cation of this enrichment biomarker through this EMA 
pathway. This strategy was designed and executed by 
the Critical Path for Parkinson’s (CPP), a public–private 
partnership coordinated by the Critical Path Institute 
and funded by Parkinson’s UK and its industrial part-
ners.5 The CPP brings together subject matter experts 
representing the pharmaceutical industry, academia, 
and regulatory authorities. The CPP working groups 
developed and executed a comprehensive qualification 
analysis plan, following the EMA guidance document 
for the Qualification of Novel Methodologies in Drug 
Development. The results from the modeling analyses 
were submitted to the EMA, which led to a qualification 
opinion for DAT imaging as an enrichment biomarker for 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ dopamine transporter (DAT) neuroimaging has been 
used as a diagnostic aid for Parkinson’s disease. The 
regulatory strategy toward DAT qualification as an enrich-
ment biomarker is described in this paper.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This effort formally quantified the utility of DAT as a 
clinical trial enrichment tool, through the development of a 
quantitative disease progression model.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ The underlying disease progression model allows 
sponsors to define trial- specific enrichment strategies 
for DAT.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
✔ The qualification of DAT as an enrichment biomarker is 
yet another example of how disease progression models 
are needed in order to qualify clinical biomarkers.
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clinical trials in early motor PD.6 The findings were pre-
sented via Scientific Advice mechanism with the EMA’s 
Scientific Advice Working (SAWP) Party on July 4, 2017, 
leading to the Qualification Opinion mechanism with 
EMA’s Committee for Medicinal Products for Human Use 
(CHMP), on May 28, 2018.7
METHODS
Regulatory pathway with the EMA
The regulatory strategy was designed around the pathway 
for the qualification of novel methodologies in drug develop-
ment.4 This process started with the submission of a letter 
of intent and briefing package that included: (i) the proposed 
context of use (COU; Table 1), (ii) a comprehensive analy-
sis plan (e.g., statistical model development and evaluation, 
assessment of magnitude of motor scores worsening, and 
enrichment utility), and (iii) target data sets to support the 
proposed analysis plan. This, in turn, triggered a formal re-
view by the EMA’s SAWP, followed by a face- to- face meeting 
in which the SAWP issued formal scientific advice for opti-
mization and finalization of the COU statement and analysis 
plan. Subsequently, the modeling analyses were executed, 
and, upon their completion, a final qualification package was 
submitted to the EMA for a final review and SAWP meeting. 
This final meeting was aimed at reaching a final determina-
tion if the presented results constituted supporting evidence 
for the proposed COU. Afterward, the SAWP met with the 
CHMP, who made the final decision to issue a qualification 
opinion.8
Data sources
Integrated patient- level data from the Parkinson’s 
Progression Markers Initiative (PPMI) and the Parkinson 
Research Examination of CEP- 1347 Trial (PRECEPT) 
were analyzed.5,6 These data correspond to a total of 672 
subjects diagnosed with early-stage PD and a total of 
4,521 observations in the baseline to 25- month interval7 
(Figure 1).
Definition of biomarker status
Dopamine transporter neuroimaging status was treated 
as a binary covariate based on visual reads, with individ-
uals classified as either having scans without evidence 
of dopaminergic deficit (SWEDD; or biomarker-negative) 
or having scans with evidence of dopaminergic deficit 
(biomarker-positive).
Harmonization of motor scores
The transformation of the individual Unified Parkinson’s 
Disease Rating Scale (UPDRS) part III subtotal score in 
PRECEPT to the respective Movement Disorder Society 
(MDS)- UPDRS part III subtotal score in PPMI relied on a 
previously derived method.9 This allowed motor score inte-
gration across both studies.
Statistical modeling and clinical trial simulation
As described by Conrado et al.,7 an early motor PD pro-
gression model was developed using the harmonized 
MDS- UPDRS part III as the end point. Through this model, 
the difference in progression rate between SWEDDs and 
DAT deficit subjects and utility of DAT- based enrichment 
was determined.
In the PD progression model, the time course of the har-
monized motor scores was described using a linear mixed- 
effects model. Prespecified covariates were the effect of 
biomarker status in baseline motor scores and progression 
rate and the effect of study in baseline motor scores to ac-
count for potential score differences between the PPMI and 
PRECEPT populations. Additional exploratory covariates 
included the effect of age in baseline motor scores and in 
progression rate given the neurodegenerative nature of PD 
and the effect of study in progression rate to investigate po-
tential rate differences between the PPMI and PRECEPT. 
The final model included all the prespecified covariates (Eq. 
S1, Supplementary Material), and all statistically significant 
exploratory covariates.
Monte Carlo– based clinical trial simulations were per-
formed to compare the statistical power vs. sample size in tri-
als with and without DAT imaging enrichment. Enriched trials 
had only subjects with DAT deficit, whereas nonenriched tri-
als included 15% of SWEDD subjects.7 The statistical power, 
defined herein as the probability of detecting a drug effect 
of 50% reduction in progression rate, was calculated as the 
proportion of trials for which the drug effect on progression 
rate was beneficial with a two- tailed P value lower than 0.05.
Additional detailed information on the methods has been 
published in ref. 7.
RESULTS
Disease progression model
The final linear mixed- effects model included: (i) effect of 
biomarker status on baseline, (ii) effect of biomarker sta-
tus on progression rate, (iii) effect of study on baseline, and 
(iv) effect of age on baseline7 (Figure 2). Model diagnostics 
suggested an adequate fit of the longitudinal changes in the 
harmonized score.7 The main findings were:
• The estimated effect of SWEDD on progression rate was 
−0.13 points/month (90% confidence interval (CI): −0.23 
to −0.04; one-tailed P value = 0.01). This means that 
SWEDDs have an average monthly progression in the 
harmonized motor scores that is 0.05 (90% CI: −0.04 to 
0.13) points/month or 0.13 point/month lower than those 
with DAT deficit (0.18 points/month; 90% CI: 0.14−0.21).
• The estimated effect of SWEDD on baseline was −7.69 
(90% CI: −9.4 to −6.04) points; hence, SWEDDs have an 
average baseline harmonized motor score that is 7.69 
points lower than those with DAT deficit.
• The estimated effect of year of age on baseline was 0.19 
(90% CI: 0.14−0.24) points, which means that on average, 
the baseline harmonized motor score increases by 0.19 
points for each year of age. Thus, the baseline score for 
a typical 60 year old subject with DAT deficit is expected 
to be 21.54 points.7
Magnitude of motor scores worsening between 
biomarker statuses
The magnitude of motor scores worsening (defined as 
change from baseline at 24 months) in DAT deficit and 
SWEDD subjects was 4.28 (90% CI: 3.45−5.08) and 1.12 
242
Clinical and Translational Science
Dopamine Imaging to Enrich Parkinson Trials
Romero et al.
(90% CI: −0.98 to 3.1), respectively. The average difference 
between biomarker statuses was −3.16 (90% CI: −0.96 to 
−5.42) points, indicating that subjects with DAT deficit have 
an average of 3.16 points higher (worse) 24- month change 
from baseline motor score than SWEDDs.
Clinical trial simulations and statistical power
Simulated trial designs were placebo- controlled, parallel, 
and crossover with total duration of 12 and 24 months. For 
each design, 2,000 enriched and nonenriched clinical tri-
als were simulated, yielding a total of 8 scenarios. For such 
scenarios, DAT imaging- based enrichment strategy was 
estimated to allow a 20–30% reduction of trial size.
DISCUSSION
The following were considered key issues to support the 
regulatory discussion:
1. Biomarker deficit status (SWEDD vs. DAT deficit) as a 
predictor of disease progression, even when the dif-
ference in baseline severity has been accounted for.
Table 1 Description of context of use statement
COU component Description
General area Enrichment biomarker for clinical trials in early motor PD
Target population for 
use
Patients with early motor PD, defined by the UK Brain Bank Criteria10 as outlined below:
• Having at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); 
OR either asymmetric resting tremor or asymmetric bradykinesia. 
o Based on above criteria, combinations could include: resting tremor/bradykinesia, bradykinesia/rigidity, and resting 
tremor/rigidity.
o Symptom(s) or signs may include bradykinesia, a 4−6 Hz resting tremor, muscle rigidity, or postural instability not 
caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction.
• Hoehn and Yahr stage I or II at baseline. 
o Although postural instability is a common feature in PD, based on the inclusion criterion of Hoehn and Yahr Stage I or II, 
postural instability would not be expected in the target population.
Stage of drug 
development for use
All clinical stages of early PD drug development, including proof- of- concept, dose- ranging through to confirmatory clinical 
trials. This is not intended for candidate therapies for more advanced stages of PD, such as drugs to treat L- Dopa–induced 
dyskinesia.
Intended application Purpose: The objective of this project is to apply DAT imaging as a biomarker tool to enrich subjects for clinical trials in early 
symptomatic PD by identifying subjects with a DAT deficit for possible inclusion into the study and excluding subjects who 
are unlikely to progress due to the lack of dopamine deficiency in the brain. The DAT imaging is intended to be used after 
the clinical criteria for early PD have been satisfied.
1. Potential candidates for PD clinical trials will be evaluated for the presence of at least two motor signs of PD, as described 
in the target population description of this section (according to the PPMI and PRECEPT criteria).
2. Those individuals are then evaluated according to the UK Brain Bank step 1 Criteria for PD.
3. If the two conditions above are met, subjects will undergo the trial-specific inclusion/exclusion criteria and further clinical 
assessment for atypical Parkinsonian syndromes.
4. As a final step in the subject-selection process, molecular imaging of DAT will be performed to detect the presence or 
absence of DAT-deficiency and identify and exclude subjects defined as SWEDDs.
5. Such baseline categorization of DAT-deficiency can be applied as an enrichment biomarker that, in combination with 
specific clinical signs, can more accurately predict disease progression of motor disability in early PD patients. Such 
progression will be expressed by the motor scores of the UPDRS or MDS-UPDRS scales, which constitute reliable 
outcomes of disease progression in PD.
6. Baseline categorization of DAT-deficiency can be applied as a subject selection biomarker to enrich trial populations with 
patients more likely to progress in the motor scores of UPDRS or MDS-UPDRS scale (parts II and III) over the course of 
clinical trials, which may be up to 2 years in duration. The purpose is to exclude patients who are unlikely to show disease 
progression (SWEDD), and consequently to increase the probability of the trial conclusively demonstrating the effect of an 
effective drug in clinical trials for therapeutic interventions for early PD. Those individuals who are not SWEDDs and who 
meet all the other selection criteria will be enrolled into the trial and randomized as per the specified study design.
7. The use of DAT imaging would allow the exclusion of subjects unlikely to have the diagnosis of PD and, therefore, prevent 
them from unjustified exposure to experimental PD-specific therapies with inherent safety and tolerability risks without 
anticipated benefit.
8. The application is relevant to both symptomatic and disease-modifying candidate therapies for early PD and is independ-
ent of the mechanism of action of the new drug.
9. The use of DAT imaging for diagnostic applications are out-of-scope for this proposed COU. 
Critical  
parameters for the 
context- of- use
The context- of- use specifies that reductions of DAT, as assessed by SPECT neuroimaging, will be utilized as an adjunct to 
clinical assessments for the purposes of enriching the patient population with subjects who have increased likelihood of 
having idiopathic PD. The subjects will have an objectively confirmed motor impairment with alternative identifiable causes 
of motor impairment appropriately excluded through clinical means prior to the use of DAT neuroimaging. 
SPECT neuroimaging procedures and methodologic aspects of imaging will be performed qualitatively in accord with the 
tracer manufacturer’s specifications and consistent with the methods currently used in the multisite PPMI study. The 
proposed analysis of DAT SPECT images is by visual assessment by trained blinded readers and analysis is to be carried 
out by a single site. Such processes are expected to generate sufficiently accurate, reproducible, and robust assessment 
of DAT neuroimaging to facilitate clinical trial enrichment.
COU, Context of Use; DAT, dopamine transporter; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s 
disease; PPMI, Parkinson Progression Markers Initiative; PRECEPT, Parkinson Research Examination of CEP- 1347 Trial; SPECT, single photon emission 
computed tomography; SWEDDs, scans without evidence of dopaminergic deficits; UPDRS, Unified Parkinson’s Disease Rating Scale.
243
www.cts-journal.com
Dopamine Imaging to Enrich Parkinson Trials
Romero et al.
Because the distribution of observed baseline motor 
scores shows some degree of overlap in the baseline scores 
between SWEDD and DAT deficit subjects (Figure 3), a 
baseline- matched subset of the data was created. In this 
baseline- matched subset, DAT deficit subjects were included 
only if there was more than one SWEDD subject with the same 
observed baseline score (rounded to zero decimal places); 
likewise, SWEDD subjects were included only if there was 
more than one DAT deficit subject with the same observed 
baseline score (rounded to zero decimal places). A supple-
mentary statistical analysis was then performed using this 
baseline- matched subset. Given the association between 
biomarker status and baseline motor scores, a baseline- 
matched data set decreases the likelihood of confounding 
effects and helps investigate the separate contribution of 
baseline and biomarker status on the rate of progression. 
Results showed a significant difference in progression rate 
between the SWEDD and DAT deficit groups of −0.19 points/
month (two- tailed P value < 0.05) even after accounting for 
disease severity at baseline (Table 2).
A second supplementary analysis was performed on to-
tality of data (N = 672), including effect of baseline disease 
severity on progression rate. Such analysis yielded a differ-
ence in progression rate between SWEDD and DAT deficit 
subjects of −0.24 points/month (P value < 0.05). This pro-
vides further evidence for DAT imaging as an actual predic-
tor of disease progression (Table 3).
2. Similarities between SWEDD and DAT deficit subject 
entry criteria in PPMI and PRECEPT.
The clinical enrollment criteria for SWEDD and DAT deficit 
subjects were equivalent in PPMI and PRECEPT (i.e., SWEDD 
subjects were not recruited as a separate cohort and were not 
identified until after recruitment). In PPMI, DAT imaging was 
performed after subjects met the clinical criteria (as described 
in Table 1). SWEDD subjects were asked to remain enrolled 
and then longitudinally followed for 2 years after consenting to 
remain in the study. The baseline characteristics of PPMI and 
PRECEPT are similar (Table 4) and representative of future 
clinical trial populations with early motor PD.
3. Representativeness of PPMI and PRECEPT of the 
 external SWEDD and DAT deficit population.
Figure 2 Predicted harmonized motor scores. Subjects with and 
without DAT, dopamine transporter (DAT) deficit have an average 
monthly progression in scores of 0.18 (90% confidence interval 
(CI): 0.14, 0.21) and 0.05 (90% CI: −0.04, 0.13) points/month, 
respectively (Image reproduced from ref. 7 https://doi.org/10.1111/
cts.12492, is licensed under CC BY 4.0. ©2017 The authors.).
Figure 1 Integration of data sources and harmonization of motor scores. DAT, dopamine transporter; MDS- UPDRS, Movement 
Disorder Society- Sponsored Revision of the Unified Parkinson Disease Rating Scale; PRECEPT, Parkinson Research Examination of 
CEP- 1347 Trial.
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Subjects enrolled in PPMI and PRECEPT are repre-
sentative of the population likely to participate in PD clini-
cal trials and the target population to be selected by DAT 
neuroimaging.
Clinical studies will continue to evaluate treatment re-
sponse in earlier stages of PD, where it is known that there 
is greater uncertainty in selecting participants based on clin-
ical criteria alone. Enrolling more homogeneous populations 
in these studies can help optimize clinical trial design and 
avoid exposing subjects who are less likely to progress to 
unknown test drugs.
4. Similarity between SWEDD and DAT deficit subject 
imaging acquisition in PPMI and PRECEPT.
The technical aspects of the data acquisition of DAT 
single photon emission computed tomography (SPECT) 
images were identical between SWEDD and DAT deficit 
subjects and not a reason for dopaminergic differences 
between SWEDD and PD subjects. For PPMI, all subjects 
(SWEDD and DAT deficit) were aligned in terms of their 
imaging acquisition protocol, including the time interval 
between injection and SPECT reading (4 hours in dura-
tion). For PRECEPT, all imaging was done on a single re-
search SPECT camera, and the data were managed by 
the core laboratory research group. CPP concluded that 
the dopaminergic differences between SWEDD and DAT 
deficit subjects are not due to variations in image acquisi-
tion. The potential impact of medications on DAT imaging 
was discussed. Symptomatic agents have been shown 
not to impact ligand binding. Drugs that bind to DAT (co-
caine and amphetamines) were not permitted for PPMI 
enrollment. Antidepressants have been investigated, with 
no impact on the outcome of the visual assessments for 
DAT deficiency.
5. SWEDD subjects who experienced progression.
Possible reasons that could explain why some SWEDD 
subjects in the data set experienced progression: (i) they did 
not progress as typical patients with PD and were possibly 
dystonic tremor subjects, (ii) the test performed in these sub-
jects was affected by external conditions that might have led 
to less signal in the striatum as compared with the occipital 
cortex and, hence, a false negative.
Figure 3 Distribution of baseline scores for SWEDD and 
dopamine transporter dopamine transporter (DAT) deficit 
subjects in the Parkinson Progression Markers Initiative and 
scans without evidence of dopaminergic deficit (PRECEPT) 
integrated data set. A baseline- matched data set was produced 
to investigate the effect of baseline on rate of progression. 
PRECEPT, Parkinson Research Examination of CEP-1347 Trial; 
SWEDD, scans without evidence of dopaminergic deficit.
Table 2 Parameter estimates from the supplementary analysis using 
the baseline­ matched subset (N = 463)
Parameter Estimate P value
Intercept or baseline score 
(points)
12.55 *
Effect of PRECEPT on baseline 0.59 NS
Effect of year of age on baseline 0.08 *
Effect of SWEDD on baseline −2.41 *
Slope or progression rate (point/
month)
−0.19 *
Effect of SWEDD on progression 
rate
−0.19 *
Effect of baseline on progres-
sion rate
0.03 *
NS, indicates two- tailed P value > 0.05; PRECEPT, Parkinson Research 
Examination of CEP- 1347 Trial; SWEDDs, scans without evidence of dopa-
minergic deficits.
The estimated effect of SWEDD on progression rate of −0.19 points/month 
remains statistically significant even after accounting for the effect of base-
line. SWEDDs have a progression rate that is 0.19 points/month lower than 
that observed for dopamine transporter deficit subjects.
*Indicates two- tailed P value < 0.05.
Table 3 Parameter estimates from the supplementary analysis using 
the entire data set (N = 672)
Parameter Estimate P value
Intercept at baseline scores 
(points)
12.71 *
Effect of PRECEPT on baseline 0.79 NS
Effect of year of age on baseline 0.15 *
Effect of SWEDD on baseline −7.70 *
Slope or progression rate (point/
month)
−0.31 *
Effect of SWEDD on progression 
rate
−0.24 *
Effect of baseline on progres-
sion rate
0.02 *
Additional effect of baseline on 
progression rate in SWEDD
0.02 *
DAT, dopamine transporter; NS, indicates two- tailed P value > 0.05; 
PRECEPT, Parkinson Research Examination of CEP- 1347 Trial; SWEDD, 
scans without evidence of dopaminergic deficit.
Further support for the DAT imaging status as a predictor of disease pro-
gression rate.
*Indicates two- tailed P value < 0.05.
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As per the COU statement, diagnostic applications for 
DAT imaging are out of the scope of this work. DAT imag-
ing could identify subjects with a homogeneous motor de-
cline, allowing trial enrichment and meaningful reduction of 
sample size, regardless of the ultimate diagnosis. Moreover, 
as aforementioned, DAT imaging aspects were identical be-
tween SWEDD and DAT deficit subjects.
6. Consideration of sensitivity, specificity, and predictive 
values for DAT imaging in the proposed COU.
As discussed, DAT imaging status is a statistically and 
clinically significant predictor of disease progression. Clinical 
trial simulations based on the underlying model allow the 
estimation of trial- specific DAT imaging- based enrichment 
magnitudes regardless of the ultimate diagnosis, thus pro-
viding a useful drug development tool to optimize decision 
making. As such, traditional concepts such as sensitivity, 
specificity, and predictive values, commonly applied to di-
agnostic biomarkers, are not of relevance in this enrichment 
context.
CONCLUSIONS
These findings show that a DAT- SPECT finding of integrity 
of presynaptic dopaminergic terminals in a case of sus-
pected PD is associated with a good prognosis, whatever 
the ultimate diagnosis. Exclusion of SWEDD subjects from 
future clinical trials will improve the chance of determining 
clinical benefit of new drug candidates to treat PD.
The EMA pathway for the Qualification of Novel 
Methodologies in drug development provides a valuable 
mechanism for the review and regulatory endorsement of 
DDTs, such as biomarkers and quantitative drug develop-
ment tools. The final qualification opinion for DAT- SPECT 
imaging is publicly available.8 Regulatory endorsement 
provides sponsors with the necessary confidence to apply 
novel approaches to optimize drug development, which is 
much needed for neurodegenerative conditions such as PD.
Model- informed biomarker qualification is an efficient 
method to evaluate the utility of biomarker candidates for 
specific COU statements. The modeling approach pre-
sented herein relied on the time course of motor scores 
worsening. Traditional concepts applied to diagnostic bio-
markers (e.g., sensitivity, specificity, and predictive values) 
were not needed to demonstrate the utility of DAT imaging 
as an enrichment biomarker for trials in early motor PD.
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